LAVA Therapeutics (LVTX): Rasio rega marang prakiraan pendapatan

LVTX (Lava Tx) - tandha merek perusahaan

The automation of antibody synthesis and the integration of algorithms into drug development are driving a shift in the forward P/S for LAVA Therapeutics N.V. (LVTX), where the current metric stands at 9.10. The efficiency of this trend is bolstered by outsourcing drug production to certified CDMO plants in the Netherlands. The stability of trials is guaranteed by strict control over biocomponent supplies via express carriers, eliminating any logistical bottlenecks.

LVTX Lava Tx: Rasio kapitalisasi pasar marang pendapatan mangsa ngarep ing interval 04.07.2022 - 06.12.2025

Rincian analitis perusahaan LAVA Therapeutics (LVTX)

- data kapitalisasi bursa:
Ringkesan analisis perusahaan:Lava Tx LVTX
Produk sing diprodhuksi lavatherapeutics.com

The forward P/S ratio assesses the market value of a company relative to expected revenues, allowing for the identification of how inflationary pressures and operating expenses impact investment attractiveness. For LAVA Therapeutics N.V. (LVTX), which develops bispecific antibodies through partnerships with pharma behemoths, the forward price-to-sales trend reflects the efficiency of R&D cost management, determining capital stability during the implementation of joint strategies.

Analisis pesaing

ImmunityBio Inc - Multiplikator forward rega marang pendapatan|Multiplikator Forward P/S Immunocore Corp IMCR|JANX - Rasio rega marang prakiraan pendapatan|RCUS (arcusbio.com) - Kapitalisasi marang prakiraan pendapatan|Zymeworks Biopharmaceuticals (ZYME) - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Tango Pharma (TNGX)|Multiplikator forward rega marang pendapatan IOVA|IMTX - Prakiraan rega marang pendapatan|Multiplikator forward rega marang pendapatan XNCR (Xencor Corp)|Rasio rega marang pendapatan sing dikarepake CMPX|Multiplikator Forward P/S REPL (Replimune)|Rega forward marang dodolan LYEL|innate-pharma.com - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Pyxis Oncology|Compugen Limited (CGEN) - Rasio rega marang prakiraan pendapatan|IO Biotech, Inc. - Rega forward marang dodolan|STRO (sutrobio.com) - Multiplikator Forward P/S|Multiplikator Forward P/S MiNK Therapeutics Inc.|Rasio rega marang prakiraan pendapatan werewolftx.com (HOWL)|IMMX: Rega mangsa ngarep marang pendapatan|alxoncology.com - Multiplikator forward rega marang pendapatan|CUE - Multiplikator forward rega marang pendapatan|PDSB - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi marang dodolan sing dikarepake Sonnet BioTherapeutics Holdings SONN|MAIA: Multiplikator Forward P/S|LIMN - Rasio kapitalisasi marang dodolan sing dikarepake|Multiplikator forward rega marang pendapatan NXTC|Multiplikator Forward P/S leaptx.com|Multiplikator Forward P/S INTS|Rasio kapitalisasi marang dodolan sing dikarepake Sensei Biotherapeutics, Inc.|Multiplikator Forward P/S TOVX (Theriva Corp)|Rasio kapitalisasi marang dodolan sing dikarepake gritstonebio.com (GRTS)|kinetabio.com - Multiplikator Forward P/S|NexImmune (NEXI) - Multiplikator forward rega marang pendapatan|turnstonebio.com (TSBX) - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Vaccinex, Inc (VCNX)|Multiplikator forward rega marang pendapatan HARP